Over the past decade, our understanding of the molecular defects in cancer have been exploited to develop drugs to inhibit oncogenic signalling. While these are often initially effective, resistance is almost always inevitable in advanced cancers, due to secondary mutations that re-activate the inhibited pathway.

This virtual conference will explore a seemingly paradoxical approach to cancer therapy, based on the deliberate hyper-activation of cancer-relevant signalling pathways. Accumulating evidence suggests that this leads to cell death caused by a further activation of cellular stress responses. 

This conference will focus on ways to hyperactivate oncogenic signalling and how the vulnerabilities associated with this hyper-activated state can be identified. The conference aims to give its audience a fundamentally different perspective on ways to treat cancer.